Edition:
India

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
20 Jul 2018
Change (% chg)

$-0.01 (-1.78%)
Prev Close
$0.37
Open
$0.37
Day's High
$0.37
Day's Low
$0.34
Volume
42,291
Avg. Vol
89,500
52-wk High
$1.58
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Egalet Announces Large Regional Plan To Cover Sprix Nasal Spray
Tuesday, 29 May 2018 

May 29 (Reuters) - Egalet Corp ::EGALET ANNOUNCES LARGE REGIONAL PLAN TO COVER SPRIX® NASAL SPRAY.EGALET CORP - LARGE SOUTHEAST REGIONAL HEALTH PLAN PLACED SPRIX NASAL SPRAY IN TIER 3 COVERED POSITION EFFECTIVE IMMEDIATELY.  Full Article

Egalet Corp Says A National Pharmacy Benefit Manager Has Placed Sprix Nasal Spray In A Tier 2 Preferred Position
Monday, 7 May 2018 

May 7 (Reuters) - Egalet Corp ::EGALET CORP - A NATIONAL PHARMACY BENEFIT MANAGER HAS PLACED SPRIX NASAL SPRAY IN A TIER 2 PREFERRED POSITION EFFECTIVE IMMEDIATELY.EGALET - A NATIONAL PHARMACY BENEFIT MANAGER HAS PLACED ARYMO ER EXTENDED-RELEASE TABLETS FOR ORAL USE ONLY -CII IN TIER 3 UNRESTRICTED POSITION.  Full Article

Egalet Reports Q4 Earnings Per Share $0.03
Monday, 12 Mar 2018 

March 12 (Reuters) - Egalet Corp ::EGALET REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.03.Q4 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE $7.8 MILLION VERSUS I/B/E/S VIEW $7.6 MILLION.  Full Article

Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Egalet Corp ::BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING.  Full Article

Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Egalet Corp ::EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY.EGALET CORP - FINANCIAL TERMS OF AGREEMENT WILL NOT BE DISCLOSED.EGALET CORP - ‍ORAPHARMA WILL BEGIN PROMOTING SPRIX IN Q1 AS PART OF A TWO-YEAR AGREEMENT​.EGALET CORP - HAS TERMINATED ITS AGREEMENT WITH SEPTODONT.  Full Article

Egalet Reduces Announces Refinancing Of Existing Convertible Notes
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Egalet Corp ::EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES.EGALET CORP - ‍ENTERED INTO EXCHANGE AGREEMENTS WITH CERTAIN HOLDERS OF EGALET'S OUTSTANDING 5.50% SENIOR CONVERTIBLE NOTES DUE APRIL 1, 2020​.EGALET CORP - ‍TOTAL FACE VALUE OF COMPANY'S CONVERTIBLE DEBT WILL BE REDUCED FROM $61.0 MILLION TO $48.5 MILLION THROUGH EXCHANGE​.EGALET - TOTAL PRINCIPAL AMOUNT OUTSTANDING OF EXISTING NOTES TO BE REDUCED, MATURITY DATE OF NEW NOTES IS DEC 2024-A 5-YEAR EXTENSION FROM ORIGINAL DATE.  Full Article

Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Egalet Corp ::EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN.EGALET - FINAL APPROVAL EXPECTED TO BE GRANTED WHEN EXCLUSIVITY PERIOD EXPIRES ON OCT. 2, 2018.EGALET CORP - ‍INTRANASAL ABUSE-DETERRENT CLAIM TO BE ADDED TO ARYMO ER PRESCRIBING INFORMATION LABEL FOR ARYMO ER C-II​.  Full Article

Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Egalet Corp ::EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN.EGALET CORP - ‍EGALET-002 WAS GENERALLY WELL-TOLERATED AND NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY​.EGALET CORP - ‍STUDY OF EGALET-002 MET ITS PRIMARY ENDPOINT​.  Full Article

Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​
Tuesday, 28 Nov 2017 

Nov 27 (Reuters) - Egalet Corp ::EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​.EGALET CORP - ‍APOTEX HAS LOST RIGHT TO LAUNCH AN AUTHORIZED GENERIC VERSION OF SPRIX NASAL SPRAY​.EGALET CORP - ‍IF APOTEX IS ABLE TO SATISFY REQUIREMENTS FOR LAUNCHING AN UNAUTHORIZED GENERIC, IT WOULD BE PERMITTED TO DO SO IN SEPTEMBER 2018​.  Full Article

Egalet notified that FDA will not meet PDUFA goal data for ARYMO ER
Friday, 14 Oct 2016 

Egalet Corp : Egalet notified that FDA will not meet PDUFA goal data for ARYMO ER . Egalet Corp -FDA will not meet previously announced October 14 Prescription Drug User Fee Act (PDUFA) date for ARYMO ER . Egalet - FDA has identified no particular issue with Co's application for ARYMO ER and it is working on product label . On ARYMO ER - FDA indicated that they need more time as they have done with other abuse-deterrent opioid NDA .Egalet Corp - FDA confirms no additional scientific information or data is needed for application for ARYMO ER.  Full Article

BRIEF-Egalet Reports Q1 Loss Per Share $0.26

* EGALET CORP - NET PRODUCT SALES OF $6.3 MLN FOR QUARTER ENDED MARCH 31, 2018 COMPARED TO $5.4 MLN Source text for Eikon: Further company coverage: